Determining Minimal Residual Disease Using ctDNA Deep Sequencing
Recruiting
N/A
Interventional Study
Esophageal Adenocarcinoma
Gastric Cancer
Pancreatic Cancer
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
At a Glance
- Sex
- Any
- Study type
- Interventional
- Purpose
- Diagnostic
- Participants needed
- 34 (estimated)
- Sponsor
- Masaryk Memorial Cancer Institute · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
Preoperative neoadjuvant chemotherapy is the standard treatment for locally advanced gastrointestinal tumours. However, not all patients respond to preoperative treatment. Early identification of progression during neoadjuvant chemotherapy or diagnosis of early disease relapse during adjuvant treatment is essential to modify the treatment strategy. The aim of this project is to validate ctDNA as a…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Consent to participate in the study
* Patients with esophageal, gastric, or pancreatic cancer, stage 0-2
* Patients with locally advanced, potentially operable disease treated with systemic perioperative chemotherapy or chemoradiotherapy
* Patients with metastatic disease trea…
Contacts